drugset
drugset / Trial / NCT06677138

PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

NCT06677138 ↗

Phase 1 Completed 8 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.

Timeline

Start
2024-10-28
Primary completion
2025-03-19
Completion
2025-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefurulimab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.